AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUN 18 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - Results from a meta-analysis indicate that the influenza vaccine containing MF59 adjuvant is more immunogenic in elderly patients with chronic disease than is the conventional influenza vaccine.
"The elderly are at a higher risk of morbidity and mortality associated with influenza infection than younger adults, but get less protection from conventional vaccination," said Angelika Banzhoff and collaborators at Chiron Vaccines in Siena, Italy and Marburg, Germany. "We conducted a meta-analysis of all available data from clinical trials in the elderly on a recently introduced MF59-adjuvanted influenza vaccine to determine its immunogenicity and safety in subjects with underlying chronic disease who are at highest risk of influenza infection."
The investigators analyzed 13 trials involving 3,600 subjects who received the new influenza vaccine or the conventional vaccine without the adjuvant.
At 28 days, geometric mean hemagglutination inhibition titer (GMT) was significantly higher in elderly subjects with chronic disease who received the adjuvanted vaccine with the A/H3N2 antigen compared to those who received vaccine without antigen (p=0.004). The MF59/conventional GMT ratio was 1.37 for chronically ill older adults vaccinated with the B antigen (p=0.065) and 1.17 for those receiving the A/H1N1 antigen (p=0.41).
No serious adverse effects from the MF59-adjuvanted influenza vaccine were reported, although minor effects ...